NCT01931202View on ClinicalTrials.gov

Mechanisms of Antidepressant Non-Response in Late-Life Depression

NACompletedINTERVENTIONAL

Enrollment

138

Participants

Timeline

Start Date

February 19, 2014

Primary Completion Date

January 17, 2019

Study Completion Date

January 17, 2020

Conditions

Major Depressive Disorder

Interventions

DRUG

Escitalopram

Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.

DRUG

Placebo oral tablet

Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors

lead

New York State Psychiatric Institute

OTHER

NCT01931202 - Mechanisms of Antidepressant Non-Response in Late-Life Depression | Biotech Hunter | Biotech Hunter